Prakt. lékáren. 2008; 4(3): 127-129 [Interní Med. 2007; 9(6): 262-264]

Omega-3 mastné kyseliny a kardiovaskulární onemocnění

MUDr. Michal Vrablík Ph.D
III. interní klinika VFN a 1. LF UK, Praha

Omega-3 polynenasycené mastné kyseliny a jejich účinky nejen na kardiovaskulární systém přitahují pozornost odborné i laické veřejnosti již řadu let. Výsledkem jsou tisíce článků a řada monografií, které se zabývají především vlivem konzumace omega-3 mastných kyselin rybího (v menší míře i rostlinného) původu na kardiovaskulární systém. Zvýšení konzumace rybích olejů či doplňků s obsahem eikosapentaenové (EPA) a dokosahexaenové (DHA) kyseliny jsou součástí většiny odborných doporučení pro prevenci kardiovaskulárních příhod. Přes množství dat z laboratorních, experimentálních i klinických studií přetrvává řada otázek. Jaký typ a forma omega-3 mastných kyselin je z hlediska kardiovaskulárního systému nejvhodnější? Jaká je vhodná denní dávka? Který z mnoha mechanizmů účinku rybích olejů je nejdůležitější při snižování rizika cévních příhod? Jaká je tolerance potravinových doplňků s obsahem rybích olejů? Na některé z mnoha otázek se pokusíme najít odpovědi v následujícím textu.

Keywords: omega-3 mastné kyseliny, rybí olej, kardiovaskulární onemocnění, eikosapentaenová kyselina, dokosahexaenová kyselina

Published: June 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vrablík M. Omega-3 mastné kyseliny a kardiovaskulární onemocnění. Praktické lékárenství. 2008;4(3):127-129.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bemelmans WJ, Broer J, Feskens EJ, et al. Effect of an increased intake of alpha-linolenic acid and group nutritional education on cardiovascular risk factors: the Mediterranean Alpha-linolenic Enriched Groningen Dietary Intervention (MARGARIN) Study. Am J Clin Nutr 2002, 75: 221-7. Go to original source... Go to PubMed...
    2. Burr ML, Fehily AM, Gilbert JF et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989; 2: 757-761. Go to original source... Go to PubMed...
    3. De Backer G, Ambrosioni E, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice, Eur Heart J 24 (2003), pp. 1601-1610. Go to original source... Go to PubMed...
    4. Grimsgaard S, Bonaa KH, Hansen JB et al. Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on hemodynamics in humans. Am J Clin Nutr 1998; 68: 52-59. Go to original source... Go to PubMed...
    5. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354: 447-455.
    6. Maresta A, Balduccelli M, Varani E et al. Prevention of postcoronary angioplasty restenosis by omega-3 fatty acids: main results of the Espent for Prevention of Restenosis Italian Study (ESPRIT). Am Heart J 2002; 143: E5. Go to original source... Go to PubMed...
    7. Mori TA, Bao DQ, Burke V et al. Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. Hypertension 1999; 34: 253-260. Go to original source... Go to PubMed...
    8. Mori TA, Beilin LJ. [omega] 3 Fatty acids and inflammation. Curr Atherosclerosis Rep 2004; 6: 461-467. Go to original source... Go to PubMed...
    9. Mori TA, Burke V, Puddey IB et al. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr 2000; 71: 1085-1094. Go to original source... Go to PubMed...
    10. Mori TA, Woodman RJ, Burke V et al. Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers, in treated-hypertensive Type 2 diabetic subjects. Free Rad Biol Med 2003; 35: 772-781. Go to original source... Go to PubMed...
    11. Mori TA, Woodman RJ. The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans. Curr Opin Clin Nutr 2006, 9(2): 95-104. Go to original source... Go to PubMed...
    12. Morris MC, Sacks F, Rosner B. Does fish oil lower blood pressure: a meta-analysis of controlled trials. Circulation 1993; 88: 523-533. Go to original source... Go to PubMed...
    13. Mourek J a kol. Omega-3 mastné kyseliny. Zdraví a vývoj. Triton 2007, Praha/Kroměříž, s. 174.
    14. Smith SC, Allen J, Blair SN et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update, Circulation 2006, 113: 2363-2372. Go to original source... Go to PubMed...
    15. Vaverková H, Soška V, Rosolová H, Češka R, Cífková R, Freiberger T, Piťha J, Poledne R, Štulc T, Urbanová Z, Vrablík M. Doporučení pro diagnostiku a léčbu dyslipidemií v dospělosti, vypracované výborem České společnosti pro aterosklerózu. Vnitr Lek 2007, 53(2): 181-97. Go to PubMed...
    16. von Schacky C. The role of omega-3 fatty acids in cardiovascular disease, Curr Atheroscler Rep 2003, 5: 139-145. Go to original source... Go to PubMed...
    17. Wang C, Harris WS, Chung M et al. N-3 Fatty acids from fish or fish-oil supplements, but not -linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am J Clin Nutr 2006, 84: 5-17. Go to original source... Go to PubMed...
    18. Woodman RJ, Mori TA, Burke V et al. Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrilolytic and vascular function in Type 2 diabetic patients. Atherosclerosis 2003; 166: 85-93. Go to original source... Go to PubMed...
    19. Yokoyama M, Origasea H for the JELIS Investigators. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). Am Heart J 2003, 146: 613-620. Go to original source... Go to PubMed...
    20. Zhang J, Sasaki S, Amano K et al. Fish consumption and mortality from all causes, ischemic heart disease, and stroke: an ecological study. Prev Med 1999; 28: 520-529. Go to original source... Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.